NASDAQ · REGN

Regeneron Pharmaceuticals, Inc.

Healthcare · Biotechnology

$793.26▼ 1.78% ($14.39)at close

After hours$793.00▼ 0.03%7:40 PM ET

52-week

$541.00$859.34

What the market price implies · Reverse DCF

To support a price of $793.26, this model requires revenue to grow by 7.41%/yr over the next 10 years, compounded annually.

Historical revenue grew by -2.81%/yr over the past 4 years. The required annual growth rate is 10.21 percentage points higher.

Selected forecast · Base scenario

4.62%/yr · actual 10-year annualized revenue growth

Year 1 growth: 7.23%

Market-implied · Base operating assumptions + edited margins

7.41%/yr · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

Valuation

Recommended · Revenue & margin DCF

Price used

$793.26

Estimated value / share

$664.68

Base scenario

This estimate is 16.21% below the price used.

USD · TTM ending 2026-06-30

Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.

Year 1 growth 7.23% · Ending margin 25.56% · Discount rate 7.57%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 10, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 11, 2026, 1:13 AM UTC · provider

Why this method?

The current business still looks structurally different from what it should look like in steady state, so a revenue-and-margin transition model is more honest than compounding current FCFF.

Is FCFF positive and has it been for 3+ consecutive years? 13 consecutive positive FCFF years are available.

Is FCFF stable (not swinging >30% year to year)? The largest recent FCFF swing is 22.4%.

Do you have 5+ years of positive FCFF history? 13 consecutive positive FCFF years are available.

Is the business model structurally similar to what it should be in 10 years? Revenue is still growing 16.7%, above the 15.0% maturity threshold, so a steady-state FCFF model would lean too heavily on a business still scaling.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

1Y Price: 42.72%Revenue (TTM): 9.29%FCF (TTM): -8.39%P/FCF: 50th pct

What changed

The stock rose 42.72% over the last year. Revenue grew 9.29% over the trailing twelve months. Operating margin moved from 27.02% to 25.56%. Free cash flow declined 8.39% over the trailing twelve months.

What the market seems to be pricing

The stock has moved higher with no clear directional signal from operating metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.

What would invalidate this read

Operating margin currently stands at 25.56%. A decisive move in revenue — currently up 9.29% — would be the clearest signal to resolve the ambiguity.

Performance

Return analysis

Company profile

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses.

CEOLeonard S. Schleifer

SectorHealthcare

IndustryBiotechnology

Employees15,410

IPO dateApr 2, 1991

https://www.regeneron.com

Market multiples

Forward P/E—

EV/EBITDA13.81

Enterprise value$80.33B

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth16.73%

Gross margin84.86%▼0.8ppvs FY2024

Operating margin25.56%▼3.2ppvs FY2024

ROE14.04%▼0.8ppvs FY2025

Analyst consensus

RatingBuy

Target price$827.71▲4.34%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Oct 28, 2026

Q4 FY26 · EPS est $16.04 · Revenue est $4.55B

View

Dividends

$3.70/shareQuarterlySafe

REGN pays a dividend with a 0.47% dividend yield, covered 11.0× by free cash flow.

Dividend Yield

0.47%

Annual Div / Share

$3.70

CAGR

—

Payout Ratio

8.74%

Safe

Dividend Growth Rate

Dividend Safety

10/10Safe

Income Projection

Invest

Growth rate:

Reinvest dividends

Today

$5/yr

$0/mo

In 5 yrs

$5/yr

$0/mo

In 10 yrs

$5/yr

$0/mo

Today	In 5 yrs	In 10 yrs
$5/yr $0/mo	$5/yr $0/mo	$5/yr $0/mo

Analysis

Dividend Strengths

Well-covered by free cash flow

The dividend is covered 11.0× by free cash flow, indicating the company generates sufficient cash to sustain and potentially grow the payout without straining its finances.

Risks to Watch

No strong risk signal stands out from the latest period pair.

NASDAQ · REGN

Regeneron Pharmaceuticals, Inc.

Healthcare · Biotechnology

$793.26▼ 1.78% ($14.39)at close

After hours$793.00▼ 0.03%7:40 PM ET

52-week

$541.00$859.34

What the market price implies · Reverse DCF

To support a price of $793.26, this model requires revenue to grow by 7.41%/yr over the next 10 years, compounded annually.

Historical revenue grew by -2.81%/yr over the past 4 years. The required annual growth rate is 10.21 percentage points higher.

Selected forecast · Base scenario

4.62%/yr · actual 10-year annualized revenue growth

Year 1 growth: 7.23%

Market-implied · Base operating assumptions + edited margins

7.41%/yr · flat 10-year annualized revenue growth

Valuation

Recommended · Revenue & margin DCF

Price used

$793.26

Estimated value / share

$664.68

Base scenario

This estimate is 16.21% below the price used.

USD · TTM ending 2026-06-30

Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.

Year 1 growth 7.23% · Ending margin 25.56% · Discount rate 7.57%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 10, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 11, 2026, 1:13 AM UTC · provider

Why this method?

The current business still looks structurally different from what it should look like in steady state, so a revenue-and-margin transition model is more honest than compounding current FCFF.

Is FCFF positive and has it been for 3+ consecutive years? 13 consecutive positive FCFF years are available.

Is FCFF stable (not swinging >30% year to year)? The largest recent FCFF swing is 22.4%.

Do you have 5+ years of positive FCFF history? 13 consecutive positive FCFF years are available.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

1Y Price: 42.72%Revenue (TTM): 9.29%FCF (TTM): -8.39%P/FCF: 50th pct

What changed

What the market seems to be pricing

What would invalidate this read

Operating margin currently stands at 25.56%. A decisive move in revenue — currently up 9.29% — would be the clearest signal to resolve the ambiguity.

Performance

Return analysis

Company profile

CEOLeonard S. Schleifer

SectorHealthcare

IndustryBiotechnology

Employees15,410

IPO dateApr 2, 1991

https://www.regeneron.com

Market multiples

Forward P/E—

EV/EBITDA13.81

Enterprise value$80.33B

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth16.73%

Gross margin84.86%▼0.8ppvs FY2024

Operating margin25.56%▼3.2ppvs FY2024

ROE14.04%▼0.8ppvs FY2025

Analyst consensus

RatingBuy

Target price$827.71▲4.34%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Oct 28, 2026

Q4 FY26 · EPS est $16.04 · Revenue est $4.55B

View

Dividends

$3.70/shareQuarterlySafe

REGN pays a dividend with a 0.47% dividend yield, covered 11.0× by free cash flow.

Dividend Yield

0.47%

Annual Div / Share

$3.70

CAGR

—

Payout Ratio

8.74%

Safe

Dividend Growth Rate

Dividend Safety

10/10Safe

Income Projection

Invest

Growth rate:

Reinvest dividends

Today

$5/yr

$0/mo

In 5 yrs

$5/yr

$0/mo

In 10 yrs

$5/yr

$0/mo

Today	In 5 yrs	In 10 yrs
$5/yr $0/mo	$5/yr $0/mo	$5/yr $0/mo

Analysis

Dividend Strengths

Well-covered by free cash flow

The dividend is covered 11.0× by free cash flow, indicating the company generates sufficient cash to sustain and potentially grow the payout without straining its finances.

Risks to Watch

No strong risk signal stands out from the latest period pair.